We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cerenis Reports Positive Results for Phase 1 Study of CER-001 for the Treatment of Cardiovascular Disease
News

Cerenis Reports Positive Results for Phase 1 Study of CER-001 for the Treatment of Cardiovascular Disease

Cerenis Reports Positive Results for Phase 1 Study of CER-001 for the Treatment of Cardiovascular Disease
News

Cerenis Reports Positive Results for Phase 1 Study of CER-001 for the Treatment of Cardiovascular Disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cerenis Reports Positive Results for Phase 1 Study of CER-001 for the Treatment of Cardiovascular Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cerenis Therapeutics has announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute coronary syndromes.

Results of the completed study provide evidence that the investigational therapy was safe and well-tolerated at all dose levels evaluated, including those intended for future clinical development.

The Phase 1 randomized, double-blind, placebo-controlled, cross-over, single rising dose study of 32 healthy dyslipidemic human volunteers, was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous infusions of CER-001.

In this study, each subject received dosages up to 45 mg/kg and placebo in a two period crossover design. No drug related adverse events were reported for CER-001, and cholesterol mobilization was observed at dose levels of 2mg/kg and higher.

The results from this study were consistent with pre-clinical findings in demonstrating evidence of dose-related cholesterol mobilization, as well as evidence of substantial increases in HDL-cholesterol levels. Because of these properties, we believe that administration of CER-001 may promote reverse cholesterol transport and stimulate cholesterol removal in patients.

“These positive results represent an important milestone for the CER-001 program and Cerenis’ approach to developing potent HDL mimetics.” said Jean-Louis Dasseux, CEO of Cerenis. “The data are strongly supportive of continued clinical development of CER-001 as a treatment for patients with high-risk atherosclerosis, including acute coronary syndromes.”
Advertisement